You reiterated your +20-30% long term revenue growth outlook (ex. Coronavirus) at your November Investor Day. What drives conviction in this outlook? What are the key underlying drivers?

Rational for no 1Q guide? What do you need to see before reinstating a quarterly guide?

During your 4Q call, you noted that it was too early to call an inflection point. What do you need to see to drive conviction that there is a paradigm shift underway in ortho treatment?

What are your thoughts on the sustainability of recent underlying volume trends?

The 4Q performance was impressive given the broader dental market still remains pressured amidst the pandemic. Was there an element of pent-up demand?

Can you provide an update on trends you are seeing in North America to-date? To what extent are practices reopened and back to normalized operating levels at this point? To what extent is demand returning?

You noted stronger sequential growth in China in the latest quarter – can you provide incremental color on your 4Q performance? Did you see pent-up demand?

How should we think about ASPs as we head in 2021? Can you discuss factors contributing to ongoing ASP pressure? FX vs. mix shifts vs. revenue deferral dynamics?

You raised your estimate of patients who could benefit from ortho treatment to 500M (vs.

prior 300M). Revised estimate drivers? How do you expect to reach this broader market?

Can you provide an update on newer consumer oriented marketing activities? Which strategies have been the most successful (e.g., TV vs. online vs. print; teen vs. adult; influencers)? How do you see your marketing spend shifting over time?

You’ve introduced a Bracket Buy Back program in 2Q20. Can you speak to the response/success of this program? Expect to maintain this strategy throughout 2021?

In terms of doctor-oriented efforts, are there other promotions (ex. the Switch program) you can leverage that are not directly price concessions? Bundling, co-marketing?

Can you speak to newer efforts to help doctors adopt a more digitized workflow and ultimately Invisalign (e.g., ADAPT)? How have these efforts been received?

From a broader macro perspective, can you speak to sensitivity across your business in a potentially more volatile macro environment?

Can you speak to your relationships with Aspen Dental and Heartland Dental and your DSO strategy? How would you characterize discussions with the DSOs? Profit dynamics?

Can you give us an update on your third-party financing initiatives and economics behind this offering? Will this be a key growth driver longer term? Traction?

Capital deployment priorities? M&A philosophy? What type of assets might make sense, and how large of a deal would the company consider?

Competitive Landscape Can you speak to the evolution of the doctor-directed competitive landscape (e.g., 3M, Henry Schein, DENTSPLY Sirona, and Envista Holdings)? What sort of feedback are you hearing in the marketplace? Competition across the Ortho vs. GP market?